BioXcel Therapeutics Inc Dividends
The next dividend date for BioXcel Therapeutics Inc has not yet been scheduled.
What is a Dividend Date
When we talk about a dividend date, we’re referring specifically to the ex-dividend date.
This is the date on which all stockholders will earn a dividend. Technically, a person needs to be the owner of a share of stock as of the night before the ex-dividend date in order to earn the dividend.
The ex-dividend date is different than the date when the dividend is issued. Although you earn a dividend on the ex-dividend date, that dividend is typically not disbursed to your account until several weeks later.
Most brokerages will automatically credit the dividend to your account once it’s issued.
Historical Dividends for BioXcel Therapeutics Inc (BTAI)
More About BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Owning BioXcel Therapeutics Inc Stock on the Dividend Date
If you own BioXcel Therapeutics Inc stock on the ex-dividend date, then you earn the associated dividend.
Theoretically, the price of BioXcel Therapeutics Inc stock should go down by the amount of the dividend (in addition to any other pressures that market forces have on the price of BioXcel Therapeutics Inc stock).
Therefore, it is typically not expected that there is any incremental profit to be gained from buying BioXcel Therapeutics Inc stock right before the ex-dividend date and then selling it immediately after. It’s not like you get the BioXcel Therapeutics Inc dividend payout for free just by doing that since there is typically an equivalent commensurate drop in the stock price.
Learning More BioXcel Therapeutics Inc Dividends
You can contact us any time if you would like to ask questions about BioXcel Therapeutics Inc dividends or anything else related to the stock market.